Navigating Neurology Clinical Trials: Growth Prospects from 2022 to 2032

 

The global neurology clinical trials industry is expected to grow from US$ 5.7 billion in 2022 to US$ 10.5 billion by 2032, at a CAGR of 6.3%. The growth of the market is attributed to the rising prevalence of neurological disorders, an aging population, and technological advancements. As per the findings, the neurology clinical trials market for Huntington’s disease achieved a growth rate of 5.2% during 2017-2021. Huntington’s disease occurs in every 2.7 per 100,000 habitats worldwide. Egypt contributes to the highest number of people suffering from Huntington’s disease with 21 of every 100,000 individuals.

Neurological disorders are a group of diseases that affect the brain, spinal cord, and nerves. Some of the most common neurological disorders include Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, and epilepsy. The prevalence of neurological disorders is increasing worldwide, due to the aging population and changing lifestyles.

Get your Sample Report with Latest Market Information! https://www.futuremarketinsights.com/reports/sample/rep-gb-15859

The aging population is a major driver of the neurology clinical trials market. As people age, they are more likely to develop neurological disorders. For example, the risk of developing Alzheimer's disease doubles every five years after age 65.

Technological advancements are also driving the growth of the neurology clinical trials market. New technologies, such as artificial intelligence (AI) and machine learning (ML), are being used to develop new drugs and treatments for neurological disorders. AI and ML are also being used to improve the efficiency and accuracy of clinical trials.

Key takeaways:

  • The global neurology clinical trials market is expected to grow at a CAGR of 6.3% from 2022 to 2032.
  • The growth of the market is attributed to the rising prevalence of neurological disorders, an aging population, and technological advancements.
  • The phase II segment is expected to account for the largest share of the neurology clinical trials market during the forecast period.
  • The Alzheimer's disease segment is expected to account for the largest share of the neurology clinical trials market during the forecast period.
  • The interventional study design segment is expected to account for the largest share of the neurology clinical trials market during the forecast period.
  • North America is expected to account for the largest share of the neurology clinical trials market during the forecast period.

US to dominate the neurology clinical trials Market throughout the Analysis Period:

The US generated the highest revenue in the neurology clinical trials market in 2021.  Revenue through neurology clinical trials in the U.S. grew at a CAGR of 5.3% during 2017-2021. An increase in life expectancy and a rise in neurological disorders in the U.S. is driving the need to expand neurology clinical trials. Support from government agencies and leading pharmaceutical companies like Biogen are leading the market with anticipated revenue growth of 6.6% CAGR over the forecasted period set between 2021 and 2032.

Neurology Clinical Trials Market: Competition Insights:

At present, health organizations and pharmaceutical companies are largely aiming at expanding their manufacturing facilities, investing in R&D, and inventing new drugs for the treatment of neurological disorders. The key companies operating in the neurology clinical trials market include

  • IQVIA
  • Novartis
  • Covance
  • Medpace
  • Charles River Laboratories
  • GlaxoSmithKline
  • Aurora Healthcare
  • Biogen

Some of the recent developments by key providers of neurology clinical trials are as follows:

  • In June 2022, Novartis announced the publication of Nature Medicine of Zolgensma data. The data revealed that children with spinal muscular atrophy (SMA) treated with Zolgensma were able to retain age-appropriate motor skills such as sitting, standing, and walking independently.
  • In June 2022, Biogen joined hands with Alectos Therapeutics to develop and commercialize a small molecule therapy known as AL01811, as a possible treatment for Parkinson’s disease. The collaboration will benefit Alectos with US$ 77.5 and US$ 630 Mn for development and commercial payments respectively. Moreover, Biogen will conduct responsible for regulatory costs and manufacturing once the therapy is approved for clinical settings.
  • In June 2022, Scientists at Yale University discovered that a drug developed by Bristol Myers Squibb has the ability to repair the loss of neuronal nexus known as synapse which is the key contributor to cognitive decline. The study also stated that it has the ability to restore synaptic connections in Alzheimer’s mouse models. The drug also minimized the toxic build-up of tau protein present in the brain of animals.
  • In April 2022, Novartis announced long-term data of Phase 3 ASCLEPIOS I/II trials. The data exhibited the efficacy of Kesimpta and stated that treatment of four years will reduce the risk of three and six months of confirmed disability and fewer relapses.
  • In April 2022, FDA granted Novartis, a commercial license to manufacture Zolgensma, a multi-product gene therapy with a 170,000 square-foot facility at Durham, N.C. site to test and release Zolgensma.

Key Segments Covered in Neurology Clinical Trials Industry Survey:

Neurology Clinical Trials Market by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Neurology Clinical Trials Market by Study Design:

  • Interventional
  • Observational
  • Expanded access

Neurology Clinical Trials Market by Indication:

  • Epilepsy
  • Parkinson’s Disease
  • Huntington’s Disease
  • Stroke
  • Traumatic brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Muscle regeneration
  • Other Indications

Neurology Clinical Trials Market by Region:

  • North America Neurology Clinical Trials Market
  • Latin America Neurology Clinical Trials Market
  • Europe Neurology Clinical Trials Market
  • South Asia Neurology Clinical Trials Market
  • East Asia Neurology Clinical Trials Market
  • Oceania Neurology Clinical Trials Market
  • Middle East & Africa Neurology Clinical Trials Market

Comments

Post a Comment

Popular posts from this blog

Teleradiology Services Market Analysis And Demand With Forecast Overview To 2032

Image
 In 2022, it is expected that the Teleradiology Services Market would be worth around US$ 31,880.57 Million. By 2032, it is anticipated that the market for teleradiology services would reach US$5,598.3 Million. with a 19% CAGR growth forecast through 2032. The global Teleradiology Services Market is estimated to reach a market valuation of US$ 1,971.4 Million by the end of 2016 and register a CAGR of 21.0% over the forecast period (2016–2026). The growth of this market can be attributed to the favorable government initiatives regarding the adoption of teleradiology in order to provide early disease diagnosis. Besides, the application of modern-day technologies such as the adoption of cloud-based technologies, blockchain, and cryptocurrencies will lead to better efficiency and cost-effective solutions. Increasing Investments for the development of advanced solutions is augmenting the demand for the industry. Request Sample PDF Brochure: https://www.futuremarketinsights.com/reports/...
Read more

Non-Vascular Stents Market to 2032 – Global Analysis and Forecasts by Types, Technologies, Applications and End-User Verticals

Image
 The Non-Vascular Stents Market is expected to grow at a CAGR of  4.5%  over the forecast period. (2022 - 2032). The sector is expected to be valued at  US$ 1.21 billion  in 2022 and  US$ 1.9 billion by 2032. The global non-vascular stents market is expected to move forward in response to the growing demand for minimally-invasive procedures. Rising technological and material advancements are assisting in the development of specially designed stents for use in a variety of indications thereby fueling the overall non-vascular stents market growth. Non-vascular stents use small, precise incisions, resulting in scars that are smaller and less visible than those left by traditional surgical techniques, putting the patient's safety in jeopardy. The above-mentioned feature is anticipated to provide impetus to the non-vascular stents market adoption trends in coming years. Such a surgery is associated with a faster recovery period, resulting in a shorter hospital ...
Read more

From X-rays to AI: Veterinary Imaging Innovations of the Next Decade By 2022 to 2030

Image
  Between 2022 and 2030, the global veterinary imaging industry is expected to grow at a CAGR of 6.6%, from US$ 2.02 billion in 2022 to US$ 3.37 billion by 2030. A study by Future Industry Insights (FMI) predicted that by 2030, the worldwide veterinary imaging industry would bring in US$ 3.37 billion. The research study looks at the market development for veterinary imaging through 2030 in more than 20 nations. The report offers precise insights into some of the key players in the industry's crucial business strategies. According to the poll, investments are being made in the veterinary diagnostics industry as the trend towards pet humanization picks up speed. Additionally likely to fuel industry growth are governmental rules and a greater emphasis on preserving animal health. Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-12368 Growth will also be fueled by the expansion of the animal and pet care industry as a w...
Read more